semaglutide shortage resolved fda declaratory order february 21 2025 The FDA has issued a warning to Compounded Semaglutide & Tirzepatide 2025: – Federal judge upholds FDA's removal

If you're on semaglutide for weight management, the more relevant question is whether the strains in the formula have been clinically studied for things like body fat reduction, appetite regulation, or blood sugar support

Mounjaro, Ozempic and Rybelsus have also been shown in studies to help with weight loss in people with type 2 diabetes, but they are not specifically approved by the FDA for this use

These formulations contact oral tissues directly during administration, which can temporarily worsen the sensation of dry mouth immediately after dosing

Injection site reactions, persistent heartburn, and severe constipation affect a subset of tirzepatide users disproportionately